What is the total value of the Oracle-Cerner acquisition?

The acquisition was completed at a price of $95.00 per share in cash for Cerner's common stock. While the exact total transaction value is not explicitly stated in this 8-K, the financing through a $15.7 billion bridge loan suggests a valuation in that approximate range, potentially with additional debt or equity considerations not detailed here.

How was the acquisition financed?

The acquisition was financed primarily through a $15.7 billion unsecured delayed draw term loan credit agreement (Bridge Facility) entered into on March 8, 2022. Oracle borrowed the full amount under this facility on June 8, 2022, to fund the acquisition, repay Cerner's indebtedness, and cover related fees and expenses.

What happens to Cerner's stock after the acquisition?

Following the completion of the merger, Oracle intends to delist Cerner's shares from the Nasdaq Global Select Market and terminate the registration of its shares under the Securities Exchange Act of 1934, as amended. Cerner will become an indirect, wholly owned subsidiary of Oracle.

How will Cerner's employee equity awards be treated?

Outstanding Cerner stock options, restricted stock awards, and restricted stock unit awards were assumed by Oracle. Unvested awards were converted into corresponding Oracle equity awards, while vested awards were cancelled and exchanged for cash equal to the offer price less any exercise price, plus any dividend equivalent rights.

ORCL 8-K: Acquisitions & Dispositions & Financial Events

Summary

Oracle Corporation (ORCL) has officially completed its acquisition of Cerner Corporation, a major player in healthcare IT. The transaction, valued at approximately $95 per share, was finalized on June 8, 2022, following a tender offer that commenced in January 2022. A significant majority of Cerner shareholders opted to tender their shares, satisfying the conditions for the merger. This strategic acquisition marks a substantial expansion for Oracle, particularly into the healthcare sector, and is expected to integrate Cerner's cloud-based electronic health record (EHR) system with Oracle's cloud infrastructure. The deal was financed through a $15.7 billion bridge loan, which is due in March 2023, indicating Oracle's significant use of debt to fund this transformative acquisition. Cerner will cease to be a publicly traded company as its shares are delisted from the Nasdaq. This acquisition represents a pivotal moment for Oracle, signaling a strong commitment to diversifying its revenue streams and leveraging its cloud capabilities in the rapidly growing healthcare market. Investors will be closely watching the integration process and Oracle's ability to realize the anticipated synergies and financial benefits. The successful closure of this deal demonstrates Oracle's strategic intent to grow through significant M&A activity. The financial implications, including debt servicing and the potential impact on earnings, will be a key focus for shareholders moving forward.

Key Highlights

1Oracle Corporation has successfully completed the acquisition of Cerner Corporation for approximately $95 per share in cash.
2The tender offer for Cerner shares expired on June 6, 2022, with a significant majority of shares being tendered.
3Cerner Corporation will be delisted from the Nasdaq Global Select Market and will operate as an indirect, wholly owned subsidiary of Oracle.
4The acquisition was financed through a $15.7 billion unsecured delayed draw term loan credit agreement (Bridge Facility), with all borrowed amounts due on March 7, 2023.
5Outstanding Cerner stock options and equity awards were assumed by Oracle and converted into Oracle equity awards, with specific treatment for vested and unvested portions.
6This move significantly expands Oracle's presence in the healthcare technology sector, particularly in cloud-based solutions and electronic health records (EHR).

ORACLE CORP 8-K Report, Acquisition Completed (Jun 8, 2022)

Summary

Key Highlights

Frequently Asked Questions